European Medicines Agency CHMP Recommends EU Approval of Partner Therapeutics IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Haematopoietic Sub-syndrome of Acute Radiation Syndrome) ...Middle East

LEXINGTON, Mass., June 20, 2025 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of PTx's Marketing Authorisation Application (MAA) for IMREPLYS®...

Read More Details
Finally We wish PressBee provided you with enough information of ( European Medicines Agency CHMP Recommends EU Approval of Partner Therapeutics IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Haematopoietic Sub-syndrome of Acute Radiation Syndrome) )

Also on site :

• With Property Seized and Federal Funding Uncertain, Montana Asbestos Clinic Fights for Its Life
• Flamengo vs Chelsea Preview, prediction, lineups, betting tips & odds .. FIFA Club World Cup 2025
• Erdogan vows to boost Turkey’s missile production as Israel-Iran war escalates